Master EU Pharmacovigilance with Confidence

The 7th Good Vigilance Practice (GVP) Course organized by Semmelweis University delivers a comprehensive, practice-oriented training on European Union pharmacovigilance requirements. The program is fully aligned with current EU GVP legislation and focuses on both regulatory compliance and real-world implementation.

Why This Course Matters

Pharmacovigilance is a rapidly evolving regulatory field. This course provides a structured, end-to-end overview of all EU GVP Modules, complemented by insights into emerging trends, novel regulatory challenges, and high-impact developments shaping pharmacovigilance today.

Participants gain not only theoretical knowledge, but also practical guidance directly applicable to daily pharmacovigilance activities.

Comprehensive Curriculum Covering All GVP Modules

The curriculum includes a detailed review of all EU-level pharmacovigilance legislation and GVP Modules, delivered in a logical and easy-to-follow structure.

Core Topics

  • Full overview of EU GVP Modules (I–XVI)
  • Roles and responsibilities within pharmacovigilance systems
  • Signal management, risk management, and benefit–risk evaluation
  • Pharmacovigilance system management and oversight

Extended & Emerging Topics

  • Medical device vigilance and interface with pharmacovigilance
  • Pharmacovigilance inspections and audit readiness
  • Latest academic research and scientific developments
  • Emerging regulatory expectations and future trends

Expert-Led Training

All modules are delivered by a distinguished faculty of regulatory authority representatives and senior industry experts. This ensures that participants benefit from:

  • First-hand regulatory insight
  • Practical industry perspectives
  • Real-world case examples and best practices

Who Should Attend?

This course is primarily designed for pharmacovigilance professionals, but it also offers significant value for experts working in related disciplines:

  • Pharmacovigilance specialists and safety scientists
  • Regulatory affairs professionals
  • Medical affairs professionals
  • Quality assurance and compliance experts
  • Healthcare professionals involved in patient safety

The content is suitable for both experienced professionals seeking an update and those aiming to strengthen their regulatory foundation.

Industry-Recognized Certification

Upon successful completion of the course, participants receive a certificate recognized by the pharmaceutical industry, confirming their knowledge of EU Good Vigilance Practice (GVP).

The certificate is also accepted as external pharmacovigilance training, supporting regulatory compliance, audits, and continuous professional development.

What You Will Gain

By completing the course, participants will:

  • Gain a thorough understanding of EU pharmacovigilance requirements
  • Improve confidence in applying GVP principles in practice
  • Stay up to date with current and emerging regulatory expectations
  • Strengthen their professional profile with an industry-recognized certificate

Take the Next Step

Advance your pharmacovigilance expertise with one of Europe’s leading academic programs.

  • Register now to secure your place
  • Download the detailed program to explore the full curriculum
  • Contact us for group registrations or institutional participation

Join the 7th GVP Course and gain a complete, practical understanding of EU pharmacovigilance.

Frequently Asked Questions

Is this course aligned with current EU GVP legislation?
Yes. The curriculum is fully aligned with the latest EU GVP requirements and regulatory guidance.

Is the certificate recognized by the pharmaceutical industry?
Yes. The certificate is recognized by the pharmaceutical industry and accepted as external pharmacovigilance training.

Is this course suitable for non-pharmacovigilance professionals?
Yes. Professionals from regulatory affairs, medical affairs, quality assurance, and healthcare will also benefit from the in-depth content.

Does the course include practical examples?
Yes. The program includes real-world case studies and practical insights from both regulators and industry experts.

Essential information:

  • Organizer: Semmelweis University, Department of Pharmacology and Pharmacotherapy
  • Accreditaion ID: SE-SZTOK/2026.II/00106
  • Audience: pharmacovigilance professionals (entry level for general training, mid-senior level for field specific information), healthcare professionals
  • Date: 17–18 September 2026
  • Language: English
  • Fee: 99 500 HUF
  • Venue: Online course via Zoom
  • Outcome: GVP Training certificate after successful written exam

List of lectures

DateAppointmentDurationTitle of the presentationPerformer
Thursday, 17 September 20268:4515Welcoming and introduction Learning outcomeDr. Mátyás Pétervári
Thursday, 17 September 20269:0030Pharmacovigilance legislative framework, current updatesDr. Mátyás Pétervári
Thursday, 17 September 20269:3045GVP Modul I - Pharmacovigilance systems - What makes a good PV system?Jan Petracek
Thursday, 17 September 202610:1545GVP Modul II - Pharmacovigilance System Master FileDr. Barbara Reithauser-Nyíri
Thursday, 17 September 202611:1545GVP Modul III - InspectionHatem Adel
Thursday, 17 September 202611:4545GVP Modul IV - Audits, and audit/inspection preparation on local siteReitthauser-Nyíri Barbara
Thursday, 17 September 202612:1560LUNCH BREAK
Thursday, 17 September 202613:1545GVP Modul VI – Management of reports of suspected adverse reactionsDr. Eszter Mátis, Nikolett László
Thursday, 17 September 202614:0045GVP Modul IX – Signal managementEnikő Plózer
Thursday, 17 September 202614:4515BREAK
Thursday, 17 September 202614:4530GVP Modul V - Risk managementsystemsEnikő Plózer
Thursday, 17 September 202615:1545GVP Modul VII - Periodic safety update reportViktória Kis
Thursday, 17 September 202616:0015GVP Modul VIII - Post-authorisation safety studies and X - Additional monitoringDr. Pallós Júlia
Thursday, 17 September 202616:1530GVP Modul XV - Safety communication and XVI - Risk minimisation measuresBalázsa Tamás
Friday, 18 September 20269:0030Challanges of drug safety considering innovative drug development.Prof. Dr. Péter Ferdinandy
Friday, 18 September 20269:3030MDR – Post-Market Safety requirementsZoltán Kormány
Friday, 18 September 202610:0030Application of novel methods in aRMM dissemination efficiency measurmentsEszter Puhl
Friday, 18 September 202610:4030Novel literature monitoring solutions in pharmacovigilanceNicole Baker PhD
Friday, 18 September 202611:1545ICSR processing - challanges and pitfallsNikolett László
Friday, 18 September 202612:0060LUNCH BREAK
Friday, 18 September 202613:0045Engagement of HCP for pharmacovigilanceDr. Máté Ádám Balázs
Friday, 18 September 202613:4545Future of efficient pharmacovigilance systemMelissa Wood
Friday, 18 September 202614:4545Vetenirary pharmacovigilanceMarton Szandra
Friday, 18 September 202615:3045Benefit-risk assessment of medicinesDr. Máté Ádám Balázs
Friday, 18 September 202616:1545Course summaryDr. Mátyás Pétervári